Alaunos Therapeutics Faces Nasdaq Delisting; Seeks Hearing

Alaunos Therapeutics, Inc. has received a written notice from Nasdaq indicating its securities are subject to delisting due to non-compliance with the minimum stockholders' equity requirement. The company intends to request a hearing before the Nasdaq Hearings Panel, which will stay any delisting action until the hearing and any granted extension. Alaunos is actively exploring strategic alternatives with the assistance of a financial advisor to improve its financial standing and regain compliance with Nasdaq's listing rules.